Evidence map›Paper›PMID 40297935›Full record

ArticleCancer2025

A framework-based guide for adapting and implementing primary care-based pediatric interventions to the pediatric oncology setting: HPV PROTECT as an exemplar.

James L Klosky, Brooke Cherven, Melissa B Gilkey, Jamie Aye, Sharon M Castellino, Maria M Gramatges, Susan Lindemulder, Thomas B Russell, Lucie M Turcotte, Paula D Campos González and 6 more

Abstract read
In one paragraph

Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

James L KloskyDepartment of Pediatrics, Emory University School of Medicine & The Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-4081-0417
Brooke ChervenDepartment of Pediatrics, Emory University School of Medicine & The Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Melissa B GilkeyDepartment of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
Jamie AyeDepartment of Pediatrics, Division of Pediatric Hematology/ Oncology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Sharon M CastellinoDepartment of Pediatrics, Emory University School of Medicine & The Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Maria M GramatgesDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, Baylor College of Medicine, Houston, Texas, USA.
Susan LindemulderDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, Oregon Health & Science University, Portland, Oregon, USA.
Thomas B RussellDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Lucie M TurcotteDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0003-4106-6172
Paula D Campos GonzálezInstitute for Cancer Outcomes and Survivorship, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
K Elizabeth SkipperInstitute for Cancer Outcomes and Survivorship, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Veronica CholletteHealthcare Systems and Interventions Research Branch, National Cancer Institute, Rockville, Maryland, USA.
Sandra A MitchellOutcomes Research Branch, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, USA.ORCID https://orcid.org/0000-0002-4153-9972
Graham A ColditzDepartment of Surgery, Washington University at St. Louis School of Medicine, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0002-7307-0291
Smita BhatiaDepartment of Pediatrics, Division of Pediatric Hematology/ Oncology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID https://orcid.org/0000-0002-7755-5683
Wendy LandierDepartment of Pediatrics, Division of Pediatric Hematology/ Oncology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Funding

Implementation of a Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors receiving Follow-Up Care in Pediatric Oncology Practices: A Cluster-Randomized TrialU01CA246567 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KLOSKY, JAMES, LANDIER, WENDY · 2020 to 2024
$3.0M
NCI NIH HHS U01 CA246567NCI NIH HHS U01CA246567
6 · The paper itself

Abstract

Pediatric oncology providers can help childhood cancer survivors protect their health by ensuring they receive routine preventive services. Management of these services by survivorship providers is necessary due to patients' suboptimal rates of re-engaging with pediatric primary care after treatment completion. This is especially the case with cancer prevention interventions, like human papillomavirus (HPV) vaccination, as survivors have greater confidence in the recommendations offered by their oncology versus primary care providers when counseling of this nature occurs. As these preventive pediatric interventions have traditionally been tested and delivered in primary care, they may lack appropriate tailoring or adaptation to the pediatric oncology setting. This article serves as a guide for using a best practice (ADAPT) framework for adapting and implementing a provider-focused intervention to increase the uptake of HPV vaccination in the pediatric oncology setting. Once the rationale and guiding principles for engaging in this process are presented, the intervention adaptation processes are illustrated via descriptions of assessment, planning, piloting, evaluation, implementation, and maintenance. Additional considerations specific to the pediatric oncology setting are also provided. By applying ADAPT or other appropriate frameworks when adapting and implementing pediatric interventions in the cancer survivorship setting, progress will be made toward establishing a gold standard in approaching these tasks. Ultimately, these collective efforts will maximize the likelihood of effective intervention delivery and reduce health risk in this vulnerable population.

Indexed as

Medical OncologyNeoplasmsPapillomavirus InfectionsPapillomavirus VaccinesPrimary Health CareCancer SurvivorsChildFemaleHumansPediatricsVaccinationPapillomavirus VaccinesHPV PROTECTHPV vaccinationimplementation scienceintervention adaptationpediatric oncologyprovider‐focused intervention

Identifiers

PMID40297935
PMCPMC12038771

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.